Efficacy and safety of gut microbiome-targeted treatment in patients with depression: a systematic review and meta-analysis

作者：Bo Pan, Yiming Pan, Yusong Huang, Yi Meng, Yuwei Hu, Xiaoyu Lian, Huizhong Shi, Ming‐Wei Wang, Guifen Xiang, Wen‐Yi Yang, Zhong Liu, Fangfang Xia · 发表于：BMC Psychiatry · 年份：2025 · DOI：10.1186/s12888-024-06438-z · 被引用次数：17 · 研究领域：Gut microbiota and health、Tryptophan and brain disorders、Clostridium difficile and Clostridium perfringens research

The study aimed to comprehensively analyze and establish a framework for evaluating the efficacy of microbiome–targeted treatment (MTT) for depression. We searched PubMed, Embase, Cochrane Library, Web of Science, and the Chinese National Knowledge Infrastructure database for randomized controlled trials (RCTs) on MTT in treating depression until October 19, 2023. A meta-analysis was conducted to evaluate the efficacy and safety of MTT. Comprehensive subgroup analyses were undertaken to explore factors influencing MTT’s efficacy in treating depression. This study was registered with PROSPERO (CRD42023483649). The study selection process identified 51,570 studies, of which 34 met the inclusion criteria. The overall pooled estimates showed that MTT significantly improved depression symptoms (SMD −0.26, 95% CI [−0.32, −0.19], I 2 = 54%) with acceptable safety. Subgroup analyses by geography showed that effectiveness was demonstrated in Asia (SMD −0.46, 95% CI [−0.56, −0.36], I 2 = 36%), while no evidence of effectiveness was found in Europe (SMD −0.07, 95% CI [−0.19, 0.05], I 2 = 55%), America (SMD −0.33, 95% CI [−0.67, 0.02], I 2 = 60%), and Oceania (SMD 0.00, 95% CI [−0.18, 0.18], I 2 = 0%). Besides, the efficacy was shown in depressed patients without comorbidities (SMD −0.31, 95% CI [−0.40, −0.22], I 2 = 0%), whereas effectiveness was poor in those with digestive disorders, such as irritable bowel syndrome (SMD −0.37, 95% CI [−0.89, 0.16], I 2 = 74%), chronic diarrhea (SMD −...